Trial Profile
A Single-arm Phase Ib/II Study of the Combination of Lenvatinib and Eribulin in Advanced Adipocytic Sarcoma and Leiomyosarcoma (LEADER Study)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 03 Jan 2023
Price :
$35
*
At a glance
- Drugs Eribulin (Primary) ; Lenvatinib (Primary)
- Indications Leiomyosarcoma; Liposarcoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms LEADER
- 03 Jan 2023 Last checked against ClinicalTrials.gov record.
- 27 Dec 2022 Planned End Date changed from 1 Dec 2022 to 30 Jun 2022.
- 13 Sep 2022 Results by deriving samples from LEADER study and assessing immune and vascular biomarkers associated with efficacy and mechanism of actions of the combination of lenvatinib and eribulin in leiomyosarcoma and liposarcoma , presented at the 47th European Society for Medical Oncology Congress